Your browser doesn't support javascript.
loading
Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the OBSERVE-PD observational study.
Fasano, Alfonso; Fung, Victor S C; Seppi, Klaus; Pirtosek, Zvezdan; Takáts, Annamária; Alobaidi, Ali; Onuk, Koray; Bergmann, Lars; Parra, Juan Carlos; Elibol, Bulent.
Afiliação
  • Fasano A; Edmond J Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, ON, Canada.
  • Fung VSC; Division of Neurology, University of Toronto, Toronto, ON, Canada.
  • Seppi K; Krembil Research Institute, Toronto, ON, Canada.
  • Pirtosek Z; Movement Disorders Unit, Westmead Hospital, Westmead, NSW, Australia.
  • Takáts A; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
  • Alobaidi A; Medical University Innsbruck, Innsbruck, Austria.
  • Onuk K; University Medical Center Ljubljana, Ljubljana, Slovenia.
  • Bergmann L; Neurological Clinic of Semmelweis University, Budapest, Hungary.
  • Parra JC; AbbVie Inc., North Chicago, IL, USA.
  • Elibol B; AbbVie Inc., North Chicago, IL, USA.
Acta Neurol Scand ; 146(2): 167-176, 2022 Aug.
Article em En | MEDLINE | ID: mdl-35607843
OBJECTIVES: In the absence of widely accepted criteria, determining when a patient with Parkinson's disease (PD) may benefit from more advanced treatments such as device-aided therapy (DAT) so far remains a matter of physician judgment. This analysis investigates how classification of PD varies across countries relative to measures of disease severity. MATERIALS AND METHODS: The OBSERVational, cross-sEctional PD (OBSERVE-PD) study included consecutive patients with PD at centers that offer DATs in 18 countries. In this subgroup analysis, we explore intercountry differences in identification of advanced versus non-advanced PD based on physician's clinical judgment, symptoms assessed using Delphi consensus criteria, use of DAT, motor and non-motor symptoms, and caregiver support. Demographic and clinical characteristics were obtained through review of medical records. RESULTS: Overall, 1342 of 2615 patients (51.3%) were assessed by physicians as having advanced PD. The proportion of patients in different countries identified as having advanced PD (24.4-82.2%) varied. In 15 of 18 countries, a greater proportion of patients with advanced PD, according to select Delphi criteria, were identified by physicians as having advanced PD than with non-advanced PD. There was a wide variability across countries in the proportion of patients with no dyskinesia, disabling dyskinesia, dyskinesia pain, and non-motor symptoms who were identified by physicians as having advanced versus non-advanced PD. CONCLUSIONS: The proportion of patients identified with advanced PD symptoms varies widely across countries, despite differences on the patients' profiles, indicating a need for objective diagnostic criteria to help identify patients who may benefit from DAT.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson Tipo de estudo: Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson Tipo de estudo: Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article